GC
Harbour BioMed sets ball rolling for Hong Kong IPO
Chinese biotechnology start-up HBM Holdings has filed for approval to float on Hong Kong’s stock exchange.
The issuer, known as Harbour BioMed, is a clinical stage biopharmaceutical company with operations across China, the Netherlands and the US.
It has appointed Bank of America, CLSA and Morgan Stanley as the sponsors for a Hong Kong IPO, according a draft prospectus submitted to the city’s bourse ...Already a subscriber? Login
